GlassScriptPhysician profile
William A Golgert
NPI 1366530412
$4,927.01
in general payments reported to CMS, 2019-2025
33 companies · $891 in 2025
The $891 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $334 · 2021: $561 · 2022: $219 · 2023: $601 · 2024: $407 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.03 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $835.27 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $634.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $486.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.01 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $310.99 | 2021-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $310.06 | 2019-2020 | |
| Horizon Therapeutics Plc | $284.11 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $258.18 | 2019-2025 | Jynarque |
| Genzyme Corporation | $147.31 | 2019 | |
| Travere Therapeutics, INC. | $142.09 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $141.23 | 2019-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $132.86 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $107.57 | 2019-2025 | Tremfya |
| Radius Health, INC. | $103.55 | 2021-2025 | Tymlos |
| Amag Pharmaceuticals, INC. | $95.53 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.47 | 2024-2025 | Jardiance |
| Amicus Therapeutics, INC. | $66.47 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $54.68 | 2025 | Lupkynis |
| Lilly USA, LLC | $52.87 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $46.81 | 2025 | Ozempic |
| Celgene Corporation | $45.56 | 2019 | |
| Fresenius USA Marketing, INC. | $41.29 | 2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $27.15 | 2019 | |
| Sandoz INC. | $26.74 | 2025 | Jubbonti |
| Ucb, INC. | $22.70 | 2025 | Bimzelx |
| Daiichi Sankyo INC. | $22.56 | 2020 | |
| Chiesi USA, INC. | $20.92 | 2025 | Elfabrio |
| Shire North American Group INC | $18.68 | 2019 | |
| Ardelyx, INC. | $18.48 | 2025 | Ibsrela |
| Nxstage Medical, INC. | $18.43 | 2022 | |
| Vifor Pharma, INC. | $14.77 | 2019 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Pfizer INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Golgert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.